San Francisco, California, United States United States
  • Overview
  • Team
  • Activities
Company description

Darmiyan develops a software platform that detects Alzheimer’s disease up to fifteen years before symptoms, from the standard, widely available clinical brain MRI alone. The company enables early detection of Alzheimer’s disease in cognitively normal people. Anyone over the age of 45 should be tested, and the company has already tested 3,000 patients.

Using just a regular brain MRI, Darmiyan’s software platform can produce brain maps that detect Alzheimer’s disease-related abnormality many years before the onset of clinical symptoms. It detects cell abnormalities at a microscopic level to reveal what a standard MRI scan cannot.